Aligos Therapeutics Doses First Participant
Aligos Therapeutics announces first participant dosed in Phase 1 study of ALG-170675
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.